Clinical experience with pirfenidone in five patients with scleroderma-related interstitial lung disease

Sarcoidosis Vasculitis and Diffuse Lung Diseases

Volumn 31, Issue 3, 2014, Pages 235-238

  Miura, Yukiko ^a,b   Saito, Takefumi ^a   Fujita, Kazutaka ^a   Tsunoda, Yoshiya ^a   Tanaka, Toru ^a   Takoi, Hiroyuki ^a   Yatagai, Yohei ^a   Rin, Shigen ^a   Sekine, Akimasa ^a   Hayashihara, Kenji ^a   Nei, Takahito ^b   Azuma, Arata ^b  

^a National Hospital Organization Ibaraki Higashi National Hospital The Center of Chest Diseases and Severe Motor Intellectual Disabilities   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

Antifibrotic agent; Interstitial lung disease; Pirfenidone; Scleroderma; Vital capacity

Indexed keywords

CYCLOPHOSPHAMIDE; PIRFENIDONE; PREDNISONE; PYRIDONE DERIVATIVE;

ADULT; AGED; ARTICLE; CAUSE OF DEATH; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DETERIORATION; FEMALE; FIBROSING ALVEOLITIS; HUMAN; INTERSTITIAL LUNG DISEASE; INTERSTITIAL PNEUMONIA; LUNG DIFFUSION CAPACITY; LUNG FUNCTION; MALE; MIDDLE AGED; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RETROSPECTIVE STUDY; SCLERODERMA; SCLERODERMA RELATED INTERSTITIAL LUNG DISEASE; TOTAL LUNG CAPACITY; VITAL CAPACITY; CASE REPORT; COMPLICATION; CONVALESCENCE; DRUG EFFECTS; LUNG; LUNG DISEASES, INTERSTITIAL; PATHOLOGY; PATHOPHYSIOLOGY; SCLERODERMA, DIFFUSE; SCLERODERMA, LOCALIZED; TIME FACTOR; TREATMENT OUTCOME;

AGED; FEMALE; HUMANS; LUNG; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; PYRIDONES; RECOVERY OF FUNCTION; RETROSPECTIVE STUDIES; SCLERODERMA, DIFFUSE; SCLERODERMA, LOCALIZED; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; VITAL CAPACITY;

EID: 84928623656     PISSN: 11240490     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (8)

1. Assassi S, Sharif R, Lasky RE, McNearney TA, Estrada-Y-Martin R, Draeger H, Nair DK, Fritzler MJ, Reveille JD, Arnett FC, Mayes MD, the GENISOS Study Group. Predictors of interstitial lung disease in early systemic sclerosis: A prospective longitudinal study of the GENISOS cohort. Arthritis Research & Therapy. 2010;12:R166.
2. McCrmick LL, Zhanf Y, Tootell E, Gilliam AC. Anti-TGF-β treatment prevents skin and lung fibrosis in murine sclerodermatous graft-versushost disease: A model for human scleroderma. J Immunol. 1999;163:5693-5699.
3. Taniguchi H, EbinaM, Kondoh Y, Ogura T, Azuma A, SugaM, Taguchi Y, Takahashi H, Nakata K, Sato A, Takeuchi M, Raghu G, Kudoh S, Nukiwa T. Pirfenidone in idiopathic pulmonary fibrosis: A phase III clinical trial in Japan. Eur Respir J. 2010;35:821-829.
4. Nannini C, West CP, Erwin PJ, Matteson EL. Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: A systematic review and meta-analysis of randomized controlled trials and obeservational prospective cohort studies. Arthritis Res Ther. 2008;10(5):R124.
5. Le Roy EC, Medsger TA Jr.Criteria for the classification of early systemic sclerosis. J Rheumatol. 2001;28:1573-1576.
6. Azuma A, NukiwaT, Tsuboi E, Suga M, Abe S, Nakata K, Taguchi Y, Nagai S, Itoh H, Ohi M, Sato A, Kudoh S for the members of the Research Group of Diffuse Lung Diseases in Japan; Double-blind, Placebo-controlled Trial of Pirfenidone in patients with Idiopathic Pulmonary Fibrosis. Am J Respir Crit CareMed. 2005;171:1040-1047.
7. Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, Arriola E, Silver RM, Strange C, Bolster M, Seibold JR, Riley DJ, Hsu VM, Varga J, Schraufnagel DE, Theodore A, Simms R, Wise R, Wigley F, White B, Steen V, Read C, Mayes M, Parsley E, Mubarak K, Connolly MK, Golden J, Olman M, Fessler B, Rothfield N, Metersky M. Scleroderma Lung Study Research Group.Cyclophosphamide versus placebo in scleroderma lung disease.N Engl JMed. 2006;354(25):2655-2666.
8. Okuda R, Hagiwara R, Baba T, Kitamura H, Kato T, Ogura T. Safety and efficacy of pirfemidone in idiopathic pulmonary fibrosis in clinical practice. RespiratoryMedicine 2013; 107: 1431-37.